Long-term outcomes following repair of nasal valve collapse with temperature-controlled radiofrequency treatment for patients with nasal obstruction

Ofer Jacobowitz MD, PhD 1 | Dale Ehmer MD 2 | Brent Lanier MD 3 | William Scurry MD 4 | Bryan Davis MD 5

1 ENT and Allergy Associates and department of Otolaryngology, Zucker School of Medicine, Hofstra University, New York, New York, USA
2 ENT Associates of Texas, Plano, Texas, USA
3 Central California Ear, Nose, and Throat Associates, Fresno, California, USA
4 Piedmont Ear Nose and Throat Associates, Winston-Salem, North Carolina, USA
5 Colorado ENT and Allergy, Colorado Springs, Colorado, USA

Correspondence
Ofer Jacobowitz, MD, PhD, ENT and Allergy Associates and department of Otolaryngology, Zucker School of Medicine, Hofstra University, 18 E 48th Street, 2nd floor, New York, NY 10017, USA.
Email: ojacobowitz@entandallergy.com

Funding statement: The study was funded by Aerin Medical. The author(s) received no financial support for the authorship and/or publication of this article.

KEYWORDS
long-term follow-up, nasal obstruction, nasal valve, radiofrequency, temperature-controlled

1 | INTRODUCTION

Chronic nasal obstruction is a common condition treated by the otolaryngologist that negatively impacts patients’ quality of life. 1 Nasal valve collapse is recognized as a common cause of chronic nasal obstruction that, if left untreated, may result in unsuccessful surgical outcomes. 2,3 Temporary treatments depend on daily use, and functional rhinoplasty surgeries are performed in the operating room, involve graft implantation, and require extensive recovery with risks of bleeding, infection, and persistent discomfort. 4–7

Temperature-controlled radiofrequency (TCRF) treatment is a minimally invasive option to reduce nasal valve–related obstruction through submucosal remodeling to improve nasal airflow. The objective of this study was to assess the long-term durability of TCRF treatment of nasal valve collapse for relief of symptoms of nasal airway obstruction through 48 months in a cohort of patients enrolled in a prospective study with previously reported results. 8,9

2 | METHODS

2.1 | Study design

Patients in this extended 48-month follow-up study were invited to participate after completing an initial 26-week study with an extension to 24 months. 8,9 The initial study was a prospective, single-arm multicenter study enrolling patients with chronic severe nasal obstruction with nasal valve collapse identified as the primary cause of obstruction. 8,9 Patients with prior nasal valve surgery or other surgical nasal procedures within the past 12 months were excluded. Medication use was not controlled during the study but patients were medically treated before surgery. Patients underwent bilateral treatment with a Vivaer device (Aerin Medical), which maintains treatment...
temperature at 60°C. The stylus tip was placed against mucosa underlying the lower edge of the upper lateral cartilage. Three to four nonoverlapping sites on the lateral nasal wall were treated for 12 seconds. No concomitant treatments were allowed. Extended follow-up assessments included use of the validated Nasal Obstruction Symptom Evaluation (NOSE) scale score, completed in person, by telephone, or through mail at 36 and 48 months postprocedure.

2.2 | Data analysis

Statistical comparisons included t tests (or Wilcoxon two-sample test) and Fisher exact tests. Longitudinal NOSE scores were analyzed using a repeated-measures linear mixed model with Tukey–Kramer comparisons; severity category distributions were analyzed using generalized linear models with visit comparisons. All available data are reported for each time point without imputation for missing values. Unless otherwise stated, NOSE scale scores are reported as least-square means and range with percentage change relative to baseline. Responders included patients with a decrease of ≥15 points on NOSE score.

3 | RESULTS

Of the 49 patients in the initial study, 39 agreed to participate in follow-up through 24 months. Of these, 27 (93.1%) were responders, defined as a decrease of ≥15 points on the NOSE score. Table 1 shows the demographic and baseline characteristics of the participants and nonparticipants.

| TABLE 1 | Demographic and baseline characteristics of participant and nonparticipant patients through the 36- and 48-month extended follow-up period |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
|         | Participants (n = 29)                                                                                                          | Nonparticipants (n = 20)                                                                 | Statistical test, p value |
| Age (years) mean (± SD, range) | 29 54.1 (± 11.9, 32.0–78)                                                                                                   | 20 46.0 (± 12.5, 24-71)                                                                 | t Test, p = 0.025 |
| 10-year age ranges (%) | Fisher exact, p = 0.255                                                                                                       | |
| 20–29 | 0 0 | 2 10.0 | |
| 30–39 | 4 13.8 | 5 25.0 | |
| 40–49 | 7 24.1 | 6 30.0 | |
| 50–59 | 8 27.6 | 5 25.0 | |
| 60–69 | 7 24.1 | 1 5.0 | |
| 70–79 | 3 10.3 | 1 5.0 | |
| Sex (%) | Fisher exact, p = 0.771                                                                                                       | |
| Men | 15 51.7 | 12 60.0 | |
| Women | 14 48.3 | 8 40.0 | |
| Race (%) | Fisher exact, p = 0.408                                                                                                       | |
| White | 29 100.0 | 19 95.0 | |
| Declined available choices | 0 0 | 1 5.0 | |
| Ethnicity (%) | Fisher exact, p = 0.162                                                                                                       | |
| Hispanic or Latino | 0 0 | 2 10.0 | |
| Not Hispanic or Latino | 29 100.0 | 18 90.0 | |
| BMI, mean (± SD, range) | 29 27.3 (± 4.8, 18.5–36.6)                                                                                                   | 20 29.5 (± 5.6, 21.6–42.7)                                                                 | t Test, p = 0.138 |
| Baseline NOSE score mean (± SD, range) | 29 81.0 (± 9.9, 65–100)                                                                                                      | 20 77.3 (± 11.2, 60-95)                                                                 | Wilcoxon two-sample test, p = 0.250 |
| 6-month NOSE Score mean (± SD, range) | 29 21.6 (± 18.6, 0–70)                                                                                                       | 20 29.3 (± 22.4, 0-90)                                                                 | Wilcoxon two-sample test, p = 0.191 |
| 6-month NOSE score responders (%) | Fisher exact, p > 0.999                                                                                                       | |
| Responders (≥15 points) | 27 93.1 | 19 95.0 | |
| Nonresponders | 2 6.9 | 1 5.0 | |

NOSE, Nasal Obstruction Symptom Evaluation.
**FIGURE 1** (A) Comparison of mean total Nasal Obstruction Symptom Evaluation (NOSE) scale scores at baseline and at 6-, 12-, 18-, 24-, 36-, and 48-month time points. Considerable improvements were noted at all follow-up times, consistent with previous work. Markers and error bars indicate means ± standard deviation. *** indicates a statistically significant \( p < 0.001 \) difference from baseline. (B) Mean NOSE scale scores by category at baseline and 6-, 12-, 18-, 24-, 36-, and 48-month time points. (C) Proportion of patients by NOSE scale severity at baseline and 6-, 12-, 18-, 24-, 36-, and 48-month time points. At baseline (pretreatment), all patients reported a NOSE scale severity score as either “severe” (48.3%) or “extreme” (51.7%). The proportion of patients in the “severe” category decreased to 10.7% at 48 months with no patients in the “extreme” category at either posttreatment time point. These differences in severity compared with baseline were statistically significant \( p < 0.001 \).
DISCUSSION

This report of patients treated with TCRF for chronic nasal obstruction attributed to nasal valve collapse provides the longest postprocedure outcome data to date for this technology. The significant postprocedure NOSE score improvements observed through 24 months for this cohort were sustained through 48 months (60.1% and 68.3% improvement from baseline at 36 and 48 months, respectively; p < 0.001) and distributed across NOSE score domains. The extent and duration of improvement observed from TCRF treatment over time in this report compares favorably with improvements observed up to 12 months following surgical nasal valve repair and functional rhinoplasty performed to address chronic nasal obstruction.10

This study was limited by its use of a single-arm design without randomized control, no control of medication usage, and significant patient attrition relative to the primary study.8 Two nonparticipants were known to have undergone subsequent surgery for nasal obstruction and it is possible that the effectiveness declined in the extended follow-up nonparticipants, although participants and nonparticipants had similar baseline characteristics and both groups experienced robust NOSE score reductions at 6 months.

In conclusion, in the longest follow-up report to date, significant and sustained improvements in symptoms of nasal airway obstruction were shown through 4 years following treatment of nasal valve collapse via a single TCRF procedure.

ACKNOWLEDGMENTS

The authors thank Jeff F. Doerbzacher, MS, for assistance in the statistical analysis. Third-party writing assistance was provided by Allison Foster, PhD, of Foster Medical Communications.

CONFLICT OF INTEREST

Drs Jacobowitz, Ehmer, and Davis are consultants for Aerin Medical, and Dr Ehmer is a speaker for Aerin. Drs Lanier and Scurry have no conflicts of interest to disclose.

REFERENCES

1. Yamasaki A, Levesque PA, Bleier BS, et al. Improvement in nasal obstruction and quality of life after septorhinoplasty and turbinoplasty surgery. The Laryngoscope. 2019;129(7):1554–1560. doi:10.1002/lary.27859
2. Hsu DW, Suh JD. Anatomy and physiology of nasal obstruction. Otolaryngol Clin North Am. 2018;51(5):853–865. doi:10.1016/j.otc.2018.05.001
3. Rhee JS, Weaver EM, Park SS, et al. Clinical consensus statement: diagnosis and management of nasal valve compromise. Otolaryngol Head Neck Surg. 2010;143(1):48–59. doi:10.1016/j.otohns.2010.04.019
4. Mohan S, Fuller JC, Ford SF, Lindsay RW. Diagnostic and therapeutic management of nasal airway obstruction: advances in diagnosis and treatment. JAMA Facial Plast Surg. 2018;20(5):409–418. doi:10.1001/jamafacial.2018.0279
5. Schuman TA, Senior BA. Treatment paradigm for nasal airway obstruction. Otolaryngol Clin North Am. 2018;51(5):873–882. doi:10.1016/j.otc.2018.05.003
6. Rhee JS, Arganbright JM, McMullin BT, Hanley M. Evidence supporting functional rhinoplasty or nasal valve repair: a 25-year systematic review. Otolaryngol Head Neck Surg. 2008;139(1):10–20. doi:10.1016/j.otohns.2008.02.007
7. Chambers KJ, Horstkotte KA, Shanley K, Lindsay RW. Evaluation of improvement in nasal obstruction following nasal valve correction in patients with a history of failed
septoplasty. *JAMA Facial Plast Surg*. 2015;17(5):347–350. doi:10.1001/jamafacial.2015.0978

8. Jacobowitz O, Driver M, Ephrat M. In-office treatment of nasal valve obstruction using a novel, bipolar radiofrequency device. *Laryngoscope Investig Otolaryngol*. 2019;4(2):211–217. doi:10.1002/ioi.2.247

9. Ephrat M, Jacobowitz O, Driver M. Quality-of-life impact after in-office treatment of nasal valve obstruction with a radiofrequency device: 2-year results from a multicenter, prospective clinical trial. *Int Forum Allergy Rhinol*. 2021;11(4):755–765. doi:10.1002/alr.22667

10. Floyd EM, Ho S, Patel P, Rosenfeld RM, Gordin E. Systematic review and meta-analysis of studies evaluating functional rhinoplasty outcomes with the NOSE Score. *Otolaryngol Head Neck Surg*. 2017;156(5):809–815. doi:10.1177/0194599817691272

**How to cite this article:** Jacobowitz O, Ehmer D, Lanier B, Scurry W, Davis B. Long-term outcomes following repair of nasal valve collapse with temperature-controlled radiofrequency treatment for patients with nasal obstruction. *Int Forum Allergy Rhinol*. 2022;12:1442–1446. https://doi.org/10.1002/alr.23019